Share this post on:

Product Name: IDH Antibody
Species Reactivity: Human
Tested Applications: Flow, IF, WB
Applications: Flow Cytometry: 0.5-1 ug/million cellsImmunofluorescence: 0.5-1 ug/mlWestern blot: 0.5-1 ug/mlOptimal dilution of the IDH antibody should be determined by the researcher.
User Note: Optimal dilutions for each application to be determined by the researcher
Predicted Molecular Weight:
Immunogen: A recombinant fragment (119 amino acid residues; aa 296-414) from the human protein was used as the immunogen for the IDH antibody.
Host Species: Rabbit
Purification: Protein A affinity chromatography
Physical State: Liquid
CAS NO.: 53-06-5
Product: Compound 401
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Conditions: Aliquot and Store at -20C. Avoid freez-thaw cycles.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: IDH1 Antibody: IDH, IDP, IDCD, IDPC, PICD, HEL-216, HEL-S-26, Cytosolic NADP-isocitrate dehydrogenase, IDH
Accession NO.:
Protein Ino:
Official Symbol: IDH1
Geneid: 3417
Background: It recognizes a 45kDa protein, which is identified as isocitrate dehydrogenase (IDH1). It belongs to the isocitrate and isopropylmalate dehydrogenases family. IDH catalyzes the third step of the citric acid cycle, which involves the oxidative decarboxylation of isocitrate, forming a-ketoglutarate and CO2 in a two-step reaction. The first step involves the oxidation of isocitrate to the intermediate oxalosuccinate, while the second step involves the production of a-ketoglutarate. During this process, either NADH or NADPH is produced along with CO2. Recently, an inactivating mutation of IDH has been implicated in glioblastoma. IDH appears to function as a tumor suppressor that, when mutationally inactivated, contributes to tumorigenesis in part through induction of the HIF-1 pathway.
PubMed ID:http://aac.asm.org/content/25/1/109.abstract

Share this post on:

Author: Betaine hydrochloride